JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

Strona główna・Stock List・Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Inc

Closed

1.71 4.27

Buy Sell

Overview

Share price change

24h

Current

Min

1.7

Max

1.71

Key metrics
By Trading Economics
Income	21M -27M
Profit margin	-176.706
Employees	166
EBITDA	9.7M -36M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+292.4% upside

Dividends
By Dow Jones
Next Earnings	10 lis 2025

Market Stats
By TradingEconomics
Market Cap	12M 112M
Previous open	-2.56
Previous close	1.71

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

1.23 / 1.45 Support & Resistance

Zentalis Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

24 paź 2025, 18:41 UTC

Earnings

Procter & Gamble to Focus on Innovation, Not Discounts, to Attract Wary Shoppers - 2nd Update

24 paź 2025, 18:31 UTC

Earnings

Correction to Procter & Gamble to Focus on Innovation

24 paź 2025, 16:25 UTC

Major Market Movers

Obook Shares Rise, Company Secures New Money Transmitter Licenses

24 paź 2025, 21:24 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

24 paź 2025, 21:24 UTC

Market Talk

Moody's Sees France With Increased Risk of Political Dysfunction -- Market Talk

24 paź 2025, 21:07 UTC

Earnings

The Score: Netflix, Amazon.com, Six Flags and More Stocks That Defined the Week -- WSJ

24 paź 2025, 20:58 UTC

Earnings

S&P 500 Climbs to New Record on Strong Earnings -- WSJ

24 paź 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

24 paź 2025, 20:40 UTC

Earnings

Intel Expects Chip Shortages on Better PC Demand. Here's Why AMD Is Winning Too. -- Barrons.com

24 paź 2025, 20:24 UTC

Earnings

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 paź 2025, 20:23 UTC

Earnings

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 paź 2025, 20:13 UTC

Earnings

These Stocks Moved the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 paź 2025, 20:07 UTC

Market Talk

Different-Cell Imputation Rose Proportionally in September CPI -- Market Talk

24 paź 2025, 19:40 UTC

Market Talk

Treasury Yields Mixed, Dollar Stronger Ahead of Fed Week -- Market Talk

24 paź 2025, 19:35 UTC

Market Talk

Oil Rally on U.S. Russia Sanctions Loses Steam -- Market Talk

24 paź 2025, 19:33 UTC

Earnings

IBM and Google Are Also Making Moves in Quantum. Don't Count Out the Bigger Players. -- Barrons.com

24 paź 2025, 19:29 UTC

Market Talk

U.S. Natural Gas Ends Week Higher on Weather Outlook -- Market Talk

24 paź 2025, 18:52 UTC

Earnings

Correction to GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24 paź 2025, 18:41 UTC

Earnings

GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24 paź 2025, 18:03 UTC

Earnings

Beyond Meat Stock Is on a Wild Ride. Why a Meme Rally Looks Undercooked. -- Barrons.com

24 paź 2025, 18:02 UTC

Earnings

Progressive Stock Got Hit After Earnings. It's Time to Buy One of America's Great Companies. -- Barrons.com

24 paź 2025, 18:00 UTC

Market Talk

U.S. Oil Rig Count Rises By Two to 420 -- Market Talk

24 paź 2025, 16:57 UTC

Earnings

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

24 paź 2025, 16:54 UTC

Market Talk

End to Canada-U.S. Trade Talks Not Seen Shifting Nearterm Outlook -- Market Talk

24 paź 2025, 16:44 UTC

Market Talk

Earnings

Amazon Retail Looks Strong as Consumer Sentiment Improves -- Market Talk

24 paź 2025, 16:39 UTC

Market Talk

Earnings

Amazon Sentiment Around AWS Seen as Improving in 3Q -- Market Talk

24 paź 2025, 16:33 UTC

Earnings

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 paź 2025, 16:23 UTC

Earnings

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 paź 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

24 paź 2025, 16:07 UTC

Earnings

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

Peer Comparison

Price change

Zentalis Pharmaceuticals Inc Forecast

Price Target

By TipRanks

292.4% upside

12 Months Forecast

Average 6.71 USD 292.4%

High 10 USD

Low 4 USD

Based on 8 Wall Street analysts offering 12 month price targets forZentalis Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to Zentalis Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

1.23 / 1.45Support & Resistance

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

There is one bearish event.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.